Open-label trial of anterior limb of internal capsule-nucleus accumbens deep brain stimulation for obsessive-compulsive disorder: insights gained.
Daniel HuysSina KohlJuan Carlos BaldermannLars TimmermannVolker SturmVeerle Visser-VandewalleJens KuhnPublished in: Journal of neurology, neurosurgery, and psychiatry (2019)
We conclude that ALIC-NAcc-DBS is a well-tolerated and promising last-resort treatment option for OCD. The cause of variability in the outcome remains unclear, and the aspect of reversibility must be examined critically. The present data from one of the largest samples of patients with OCD treated with DBS thus far support the results of previous studies with smaller samples.